Half of Australians live with chronic health conditions, over a third forced to leave their jobs as a result
Read full media release here.
Read pdf version of the full media release here.

AbbVie Australia leadership credits employees for 11th consecutive year of Best Workplaces list ranking
Read full media release here.
Read pdf version of the full media release here.

AbbVie welcomes PBS listing of SKYRIZI® (risankizumab) 150mg for severe plaque psoriasis
Contact Corporate Communications for a copy of this press release.

RINVOQ^® (upadacitinib) now reimbursed for Australians living with Severe Crohn's disease
Contact Corporate Communications for a copy of this press release.

Inflammatory bowel disease experts call for urgent action to ensure equitable, multidisciplinary care in australia as prevalence continues to rise
Read full media release here.
Read pdf version of the full media release here.

New oral treatment listed on the PBS for arthritis of the spine and pelvis
Contact Corporate Communications for a copy of this press release.

AbbVie celebrates recognition as leader in workplace gender equity
Read full media release here.
Read pdf version of the full media release here.

AbbVie announces registration of RINVOQ^® (upadacitinib) for another type of arthritis
Contact Corporate Communications for a copy of this press release.

AbbVie Australia named on prestigious Best Workplaces for Women list
Read full media release here.
Read pdf version of the full media release here.

AbbVie announces leadership changes for Australia
Read full media release here.
Read pdf version of the full media release here.

AbbVie welcomes the registration of RINVOQ® (upadacitinib) for adult patients with moderately to severely active ulcerative colitis
Contact Corporate Communications for a copy of this press release.

AbbVie’s commitment to diversity and inclusion lands them #5 on the Best Workplaces list
Read full media release here.
Read pdf version of the full media release here.

AbbVie welcomes the registration of SKYRIZI® (risankizumab) for psoriatic arthritis
Contact Corporate Communications for a copy of this press release.

RINVOQ® (upadacitinib) Now Listed on the PBS for Australia’s Most Common and Severe Form of Eczema, Atopic Dermatitis
Contact Corporate Communications for a copy of this press release.

New treatment for debilitating rheumatic diseases listed on the PBS
Contact Corporate Communications for a copy of this press release.

VENCLEXTA® (venetoclax) has now received full registration for adult patients with newly diagnosed Acute Myeloid Leukaemia who are ineligible for intensive chemotherapy
Contact Corporate Communications for a copy of this press release.

AbbVie welcomes registration of RINVOQ® (upadacitinib) for atopic dermatitis
Contact Corporate Communications for a copy of this press release.

AbbVie reinforces “it’s the people, not the place” in their ninth year of recognition as a Great Place to Work
Read full media release here.
Read pdf version of the full media release here.

AbbVie welcomes registration of RINVOQ® (upadacitinib) for two new indications
Contact Corporate Communications for a copy of this press release.

New option for Australians with certain autoimmune diseases through reimbursement of HUMIRA® (adalimumab) citrate-free formulation
Contact Corporate Communications for a copy of this press release.

Venclexta (venetoclax) PBS listed as first line therapy for Chronic Lymphocytic Leukaemia (CLL) patients unfit for chemotherapy
Contact Corporate Communications for a copy of this press release.

MAVIRET® is the first PBS listed Hepatitis C treatment available for Australians 12 years and over
Contact Corporate Communications for a copy of this press release.

New treatment for rheumatoid arthritis, RINVOQ (upadacitinib), became available on the PBS during COVID-19 lockdown
Contact Corporate Communications for a copy of this press release.

AbbVie reinvents ‘pharma culture’ and takes Australia’s #2 spot for Best Place to Work
Read full media release here.

AbbVie Completes Transformative Acquisition of Allergan
Read full media release here.

AbbVie Australia - Local Response to COVID-19 
Read here.

AbbVie welcomes Therapeutic Goods Administration (TGA) Regulatory Approval of RINVOQ® (upadacitinib)
Contact Corporate Communications for a copy of this press release.

Chris Stemple Appointed General Manager AbbVie ANZ
Read full media release here.

New biologic option for severe plaque psoriasis now available on Pharmaceutical Benefits Scheme
Contact Corporate Communications for a copy of this press release.

AbbVie welcomes Therapeutic Goods Administration (TGA) Regulatory Approval of SKYRIZI™ (risankizumab)
Contact Corporate Communications for a copy of this press release.

AbbVie ANZ Appoints New Medical Director
Read full media release here.

New targeted treatment option for patients with Chronic Lymphocytic Leukaemia (CLL) now available on the Pharmaceutical Benefits Scheme
Contact Corporate Communications for a copy of this press release.

AbbVie Welcomes TGA Regulatory Approval of VENCLEXTA® (venetoclax tablets) in Combination with Rituximab
Contact Corporate Communications for a copy of this press release.

Eight-week Hepatitis C Treatment on Pharmaceutical Benefits scheme from 1st August 2018
Contact Corporate Communications for a copy of this press release.

Announcement: Venclexta PBS Status
Contact Corporate Communications for a copy of this press release.